Clinical Trial Update: Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

View source ↗

Summary

An ongoing implementation study evaluating retention and adherence to adjuvant ribociclib therapy in HR+/HER2-negative Stage II–III breast cancer, comparing out…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: RECRUITING